Sector Update: Health Care Stocks Rise Pre-Bell Friday

MT Newswires Live

09/19

Health care stocks were rising pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.2% higher.

ARS Pharmaceuticals (SPRY) shares were up more than 4% after the company said its nasal spray neffy has received regulatory approval in Japan for the emergency treatment of allergic reactions, including anaphylaxis.

Nuvation Bio (NUVB) shares were up nearly 4% after the company said Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.

KalVista Pharmaceuticals (KALV) stock was up nearly 3% after the company said the European Commission and the Swiss Agency for Therapeutic Products, Swissmedic, have approved Ekterly for the treatment of hereditary angioedema in adults and adolescents aged 12 years and older.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2568657912"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568657912\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568657912?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-19 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568657912","market":"sh","top_or_hot":-1,"title":"Sector Update: Health Care Stocks Rise Pre-Bell Friday","media":"MT Newswires Live","content":"<html><body><p> Health care stocks were rising pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) 0.2% higher.</p><p>ARS Pharmaceuticals (SPRY) shares were up more than 4% after the company said its nasal spray neffy has received regulatory approval in Japan for the emergency treatment of allergic reactions, including anaphylaxis.</p><p><a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> (NUVB) shares were up nearly 4% after the company said Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.</p><p>KalVista Pharmaceuticals (KALV) stock was up nearly 3% after the company said the European Commission and the Swiss Agency for Therapeutic Products, Swissmedic, have approved Ekterly for the treatment of hereditary angioedema in adults and adolescents aged 12 years and older.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Health Care Stocks Rise Pre-Bell Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Health Care Stocks Rise Pre-Bell Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-19 21:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Health care stocks were rising pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) 0.2% higher.</p><p>ARS Pharmaceuticals (SPRY) shares were up more than 4% after the company said its nasal spray neffy has received regulatory approval in Japan for the emergency treatment of allergic reactions, including anaphylaxis.</p><p><a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> (NUVB) shares were up nearly 4% after the company said Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.</p><p>KalVista Pharmaceuticals (KALV) stock was up nearly 3% after the company said the European Commission and the Swiss Agency for Therapeutic Products, Swissmedic, have approved Ekterly for the treatment of hereditary angioedema in adults and adolescents aged 12 years and older.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568657912","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568657912","pubTimestamp":1758287777,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Health care stocks were rising pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.2% higher.ARS Pharmaceuticals (SPRY) shares were up","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion","KALV":"Kalvista Pharmaceuticals Inc","BK4139":"生物科技","XLV":"健康照护类股ETF-SPDR","BK4581":"高盛持仓","SPRY":"ARS PHARMACEUTICALS INC","NUVB":"Nuvation Bio, Inc.","BK4007":"制药","IBB":"生物科技指数ETF-iShares Nasdaq","BK4588":"碎股"},"translate_title":"行业更新：医疗保健股周五盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBB":1,"KALV":1,"LABU":0.6,"NUVB":1,"SPRY":1,"XBI":0.6,"XLV":1},"content_text":"Health care stocks were rising pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.2% higher.ARS Pharmaceuticals (SPRY) shares were up more than 4% after the company said its nasal spray neffy has received regulatory approval in Japan for the emergency treatment of allergic reactions, including anaphylaxis.Nuvation Bio (NUVB) shares were up nearly 4% after the company said Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.KalVista Pharmaceuticals (KALV) stock was up nearly 3% after the company said the European Commission and the Swiss Agency for Therapeutic Products, Swissmedic, have approved Ekterly for the treatment of hereditary angioedema in adults and adolescents aged 12 years and older.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}